We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Randox Acquires Microfluidic Tools and Impedence Flow Cytometer Developer Cellix Limited

By LabMedica International staff writers
Posted on 22 Jun 2023
Print article
Image: The Cellix acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space (Photo courtesy of Cellix)
Image: The Cellix acquisition expands Randox’s technical capabilities into the benchtop flow cytometry space (Photo courtesy of Cellix)

Randox Laboratories (Crumlin, UK), a global diagnostics company and developer of diagnostic biochips, has completed its acquisition of Cellix Limited (Dublin, Ireland), a developer of microfluidic tools and impedance flow cytometers for cell analysis.

Randox provides innovative diagnostic solutions for a wide range of sectors including hospitals, clinical and research laboratories, food testing, forensic toxicology, veterinary labs, and life sciences. Cellix supplies microfluidic tools and impedance flow cytometers for cell analysis and sorting to customers in life science research, cell and gene therapy discovery, development, and manufacturing. Recently, Cellix introduced its first flow cytometry product, the Inish Analyzer. This microfluidic impedance-based flow cytometer is designed for cell counting, cell viability assessment, and cell membrane analysis for transfection efficiencies. With the acquisition of Cellix, Randox has extended its technical proficiency into the benchtop flow cytometry area, reaffirming its commitment to personalized medicine and improving preventative healthcare.

“The acquisition of Cellix complements and broadens Randox’s offerings by making flow cytometry more accessible to a wider audience of scientists and clinicians,” said Dr Peter FitzGerald, Managing Director of Randox Laboratories. “We are looking forward to bringing together Cellix’s expertise in cytometry with our dedication to diagnostics and believe this combination will enable us to streamline workflows resulting in better outcomes for patients.”

“Our team is very excited to be joining forces with Randox to scale access to our technology in the broader scientific community,” added Vivienne Williams, CEO of Cellix. “Cellix’s dedicated team has worked hard developing impedance-based cytometry for cell analysis supported through programs including the Disruptive Technology Innovation Fund. With Randox’s strong global presence and dedication to R&D, we are looking forward to continuing development of our technology and expanding our customer footprint.”

Related Links:
Randox Laboratories
Cellix Limited

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.